stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation 10-Q filed Nov 4, 2026
Red flags
-
Receivables outpacing revenue
Receivables grew 49.1% while revenue grew 19.2% year over year
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 9 added · 4 removed · 51 modified; 3 with only figures updated
-
Modified
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes included in this quarterly report. The following discussion may contain forward-looking statements that reflect our plans, estimates and beliefs, which are subject to risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed under the headings “Risk Factors” and “Forward-Looking Statements” in both our Annual Report on Form 10-K for the year ended December 31, 2025 and in this quarterly report.
Columns and rows within tables may not add due to rounding.Amounts have been calculated using actual, non-rounded figures; accordingly, amountspercentagesbasis points may not recalculate, and columns and rows within tables may not add due to rounding.